Isothermal Amplification Detection Patents: Leaders & Trends 2026
- Fragmented leadership. the ranked leader holds 1,875 records but the top 5 combined are just 7.9% of all 59,807 records in scope — no single filer controls the field.
- Filings cooled after 2022. the peak year was 2022 at 801 filings, and complete-year data shows a -47% drop from 771 in 2021 to 408 in 2024.
- Claim density sits in enzymatic detection. C12Q (measuring/testing involving enzymes or DNA) covers 27.9% of all records, more than double the next largest class.
Filing growth compares 2021 (771 records) with 2024 (408) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 59,807 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Instrument-light isothermal amplification detection spans methods that amplify and detect nucleic acids without the thermal cycling hardware real-time PCR requires — loop-mediated isothermal amplification and related chemistries built for specificity, visual or colorimetric endpoint reading, and field or point-of-care deployment. The dataset in scope spans 59,807 published records filed or published between 2015 and mid-2026, indexed against claim text describing specificity, primer design difficulty, colorimetric endpoint reliability, quantification capability, and suitability comparisons against real-time PCR.
The picture that emerges is not one of a single dominant platform. Diagnostics majors, molecular-biology tool makers and university labs all hold meaningful positions, and the largest technology cluster sits in enzymatic and nucleic-acid measurement methods rather than in instrumentation. That split matters for anyone deciding whether to compete on chemistry, on device, or on workflow integration.
Filing trends and technology composition
Two views of the same 59,807-record corpus: filing activity over time, and how records distribute across IPC subclasses. Because a single record can carry several IPC codes, the class shares below sum to more than 100%.
Filing trend, 2017–2026
Filings rose from 786 in 2017 to a peak of 801 in 2022, then declined to 408 by 2024 — a complete-year drop of 47% across that three-year span. 2025 and 2026 figures are still filling in as publication lags filing by roughly 18 months, so the most recent years should not yet be read as a continued decline.
Technology composition by IPC subclass
C12Q (enzyme- and DNA-based measuring and testing) accounts for 27.9% of all 59,807 records, well ahead of C12N (microorganisms and genetic engineering) at 10.1% and G01N (material analysis and testing) at 6.4%. Lab apparatus and bioreactor classes (B01L, C12M) together sit under 4% of records, suggesting claim activity concentrates on assay chemistry rather than hardware.
Shares are the percentage of the 59,807 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Instrument-Light Isothermal Amplification Detection with Eureka
This page is one run against one query. Ask Eureka your own question about instrument-light isothermal amplification detection and every answer comes back with the patent numbers behind it.
Try EurekaA representative claim in this space
WO2021146814A1 — Ultrasensitive LAMP for malaria detection
Filed by UTI Limited Partnership, this application describes a method for detecting malaria from patient blood samples using loop-mediated isothermal amplification of Plasmodium species including P. vivax, P. ovale, P. falciparum, P. malariae and P. knowlesi, with genus- and species-specific oligonucleotide primer sets targeting regions of the 18S rRNA gene.Published 2021-07-29.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5210015A | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase | 4,079 |
| 2 | US3817837A | Enzyme amplification assay | 3,517 |
| 3 | US5130238A | Enhanced nucleic acid amplification process | 3,223 |
| 4 | US5399491A | Nucleic acid sequence amplification methods | 3,064 |
| 5 | US5854033A | Rolling circle replication reporter systems | 3,030 |
| 6 | US7115400B1 | Methods of nucleic acid amplification and sequencing | 2,272 |
| 7 | US5780225A | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and method… | 2,128 |
| 8 | US5403711A | Nucleic acid hybridization and amplification method for detection of specific sequences in which a complement… | 2,053 |
| 9 | US6174670B1 | Monitoring amplification of DNA during PCR | 2,017 |
| 10 | US5641658A | Method for performing amplification of nucleic acid with two primers bound to a single solid support | 1,969 |
Citation counts favour older, foundational filings within this searched corpus — read them as a signal of influence on later work, not as a ranking of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data says about where this field stands
Three figures worth sitting with before deciding where to file or search prior art.
No single filer controls the field
The ranked leader holds 1,875 records, and the top 5 combined reach just 4,737 records — 7.9% of everything in scope. That is a low concentration for a field this large, meaning freedom-to-operate analysis has to look well beyond the largest names.
Filing activity has cooled from its 2022 peak
After peaking at 801 filings in 2022, complete-year filings fell to 408 by 2024. Several of the largest historical assignees show 0 filings or steep YoY drops in the latest tracked year, though 2025-2026 data is still incomplete.
Claim density sits in assay chemistry, not hardware
C12Q alone touches more than a quarter of all records, and C12N adds another 10.1%. Apparatus-focused classes like B01L and C12M each sit under 2%, pointing to where claim space is comparatively open.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to instrument-light isothermal amplification detection, with the prior art for and against each one.
Who is filing, and where the gaps sit
The ranking spans 100 companies drawn from the full 59,807-record corpus. Diagnostics majors and molecular-tool suppliers occupy the top of the table, but the combined share of the leading names is modest, and co-assignee activity is thin — only 10 co-assignee pairs appear across the whole dataset, most tied to corporate parent-subsidiary structures rather than external collaboration.
A clear leader, but not a dominant one
The leading assignee's 1,875 records are well ahead of fifth place at 503 and tenth place at 361, but that gap closes quickly once you move past the top few names into a long tail of smaller filers.
Concentration stays low even at ten deep
Even combining the ten largest filers only reaches 6,748 records, 11.3% of the field. Nearly nine in ten records sit outside this group, spread across universities, regional diagnostics firms and single-filing entrants.
Filing is largely done alone
The strongest co-assignee link ties two related corporate entities together at 182 shared records; most other pairs are similarly intra-group. Cross-company joint filing is rare in this space, which limits how much can be learned from co-assignment patterns alone.
| Assignee | Recent year | YoY |
|---|---|---|
| GenProbe Inc. | 1 | -94% |
| Becton, Dickinson and Company | 0 | -100% |
| F. Hoffmann-La Roche AG | 0 | — |
| Life Technologies Corporation | 0 | -100% |
| The Regents of the University of California | 0 | -100% |
| Roche Diagnostics GmbH | 0 | -100% |
| Illumina, Inc. | 0 | -100% |
| Bio-Rad Laboratories, Inc. | 0 | -100% |
Where to take this next
The landscape data points to specific follow-up work depending on what you are trying to decide.
Check freedom-to-operate against foundational claims
The most-cited records in this corpus date back to foundational amplification and detection chemistry patents. Any new filing on core amplification mechanics should be checked against these before drafting claims.
Run a prior-art search in EurekaMap the under-claimed branches in detail
Apparatus and quantitative-readout classes show comparatively low filing density against the size of the overall field. A targeted search of those subclasses can surface where a first claim is still open.
Explore white space in EurekaTrack assignee momentum before committing R&D spend
Several historically large filers show sharp drops in the latest tracked year. Understanding whether that reflects strategic pullback or publication lag matters before reading too much into any single assignee's recent activity.
Monitor assignee activity in EurekaQuestions practitioners ask about this field
It refers to nucleic acid amplification and detection methods, such as loop-mediated isothermal amplification, that run at a single constant temperature rather than requiring the thermal cycling hardware real-time PCR depends on. This makes the chemistry suitable for portable or minimal-equipment settings, often paired with visual or colorimetric endpoint reading instead of fluorescence optics. The patent evidence in this dataset specifically indexes claims comparing specificity, primer design difficulty and suitability against real-time PCR, which is why those two approaches are so often discussed together in the same filings.
The ranking covers 100 assignees drawn from 59,807 records, with the leading company holding 1,875 records, more than three times the tenth-ranked assignee's 361. Even so, the top 5 combined account for only 7.9% of all records in scope, meaning no single company holds a dominant claim position. Diagnostics companies, molecular biology tool suppliers and academic institutions all appear among the leading names, so competitive monitoring needs to extend well past the top few filers.
Filings peaked in 2022 at 801 records and fell to 408 by 2024, a complete-year decline of 47% from the 771 filed in 2021. That said, publication typically lags actual filing by around 18 months, so 2025 and 2026 figures in any dataset are still incomplete and should not yet be read as evidence of continued decline. The safest read is that filing activity has cooled from its 2022 peak but the most recent trend line is not yet settled.
Apparatus-related IPC classes such as B01L (lab apparatus) and C12M (bioreactors and enzyme apparatus) each account for under 2% of the 59,807 records in scope, far below the 27.9% concentrated in C12Q enzymatic and DNA measurement methods. That gap suggests device-level and workflow-integration claims are comparatively under-filed relative to assay chemistry claims. Quantitative readout methods for isothermal (non-PCR) assays are another area worth checking closely, since much of the existing art focuses on qualitative or endpoint detection rather than quantification.
The most-cited records, including foundational amplification and nuclease-activity assay patents, are cited thousands of times within this corpus, which signals strong influence on how later claims were drafted rather than current enforceability. Whether an old, highly-cited patent still blocks a new filing depends on its jurisdiction-specific term and current legal status, which is not something citation count alone answers. Any freedom-to-operate check should treat high citation counts as a prompt to examine claim scope and status individually, not as a standalone reason to avoid an area.
Research Instrument-Light Isothermal Amplification Detection in depth with Eureka
Go past this page: query the whole instrument-light isothermal amplification detection corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.